Compare Wahed FTSE USA Shariah ETF (HLAL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Illumina, Inc. — how do they compare? Wahed FTSE USA Shariah ETF trades at $75.91 (market cap $1.00B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 40× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is more actively traded (51,137 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 66 Days and Illumina, Inc. for 83 Days on average.
| HLAL | ILMN | |
|---|---|---|
Market Cap | $1.00B | $39.95B |
Volume | 51,137 | 3,169,503 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $293.69 |
52-Week Low | $57.46 | $91.00 |
Typical Hold Time | 66 Days | 83 Days |
Enterprise Value | — | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.91, down 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.10 is scheduled for September 2026, indicating a long-term income component. The stock shows mixed signals with strong moving average support but overbought RSI levels.
The outlook is cautiously optimistic due to bullish moving averages, but high RSI suggests near-term pullback risk. Investment opportunity lies in technical strength, while risks include lack of recent fundamental data and potential volatility from overbought conditions. Investors should await updated financials for a clearer picture.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
